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Abstract
Background: Estimations of survival rates are diverse and the choice of the appropriate method depends on the
context. Given the increasing interest in multiple imputation methods, we explored the interest of a multiple
imputation approach in the estimation of cause-specific survival, when a subset of causes of death was observed.
Methods: By using European Randomized Study of Screening for Prostate Cancer (ERSPC), 20 multiply imputed
datasets were created and analyzed with a Multivariate Imputation by Chained Equation (MICE) algorithm. Then,
cause-specific survival was estimated on each dataset with two methods: Kaplan-Meier and competing risks. The two
pooled cause-specific survival and confidence intervals were obtained using Rubin’s rules after complementary
log-log transformation. Net survival was estimated using Pohar-Perme’s estimator and was compared to pooled
cause-specific survival. Finally, a sensitivity analysis was performed to test the robustness of our constructed multiple
imputation model.
Results: Cause-specific survival performed better than net survival, since this latter exceeded 100% for almost the
first 2 years of follow-up and after 9 years whereas the cause-specific survival decreased slowly and than stabilized at
around 94% at 9 years. Sensibility study results were satisfactory.
Conclusions: On our basis of prostate cancer data, the results obtained by cause-specific survival after multiple
imputation appeared to be better and more realistic than those obtained using net survival.
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Background
In 2012, prostate cancer represented 28.5% of all male
incident cancers in France, with 56,841 new cases, far
above lung or colorectal cancer, with 28,211 and 23,226
new cases, respectively [1]. In the early 2000s, the use of
prostatic specific antigens (PSA) as a screening test led
to a marked increase in the incidence of prostate cancer.
It persisted up to 2005, and then declined, as reported in
2013 by Rébillard et al. [2]. As observed in the USA and
certain European countries [1], the risk of presenting with
prostate cancer during life is increasing, while the risk of
death from prostate cancer is decreasing. Indeed, in 2012,
prostate cancer was the third cause of death from cancer,
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(8876 deaths), which represented 10% of all male cancer
deaths. Net survival was 70% and 90% for cases diagnosed
in 1990 and 2002, respectively [1].
In 2009, the incidence of prostate cancer was very low
for patients aged under 50 years old and the median age
at diagnosis of prostate cancer was 70 years old. It is thus
a cancer of the elderly. In this context, competing risks of
death are particularly important to be taken into account
given the patient’s advanced age. Indeed, patients may die
from causes other than prostate cancer. Thus, survival due
to prostate cancer may be more difficult to estimate.
Estimations of survival rates are diverse and the choice
of the appropriate method depends on the context. More-
over, obtaining the true cause of death is difficult in order
to estimate cause-specific survival and it may be inaccu-
rate. Some methods are very sensitive to the mortality
rate of the general population which may be subject to
significant variability.
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Recently, the recommendedmethod [3, 4] for estimating
net survival (survival if the cause of death under con-
sideration is the only cause of death) is Pohar-Perme’s
estimator [5]. It is based on the mortality rate of the
general population. Thus, for diseases such as prostate
cancer, Pohar-Perme’s net survival can exceed 100%,
because populationmortality tables are not representative
of men presenting with prostate cancer. Moreover, Pohar-
Perme’s method had been criticized by Dickman et al.
[6], who showed that Pohar-Perme’s estimator may lead
to “increased variability and lack of stability for long-term
survival, particularly for older age groups”.
Given the increasing interest in multiple imputation
methods, when several causes of death are observed
and/or when a representative sample of causes of death
is completed and validated by experts, we explored the
interest of a multiple imputation approach to estimate
cause-specific survival.
The use of multiple imputation in survival analysis is
now widespread. However, Goetghebeur and Ryan [7],
Andersen et al. [8], Lu and Tsiatis [9], Gao and Tsiatis [10],
Lu and Liang [11], Bakoyannis et al. [12] and Sen et al. [13]
all proposed methods for estimating regression parame-
ters, but not for estimating survival function. Only a few
authors have proposed methods to estimate cumulative
incidence, see for example Lee et al. [14, 15], Nicolaie et al.
[16] or Moreno-Betancur and Latouche [17].
Our aim was to compare three measures:
• the results of Pohar-Perme’s net survival based on the
database without causes of death
• the pooled cause-specific survival of Kaplan-Meier
[18] after multiple imputation, when censoring
other-cause deaths
• the pooled cause-specific cumulative incidence
estimator after multiple imputation, accounting for
deaths due to other causes as competing risks.
In the next section, European Randomized Study of
Screening for Prostate Cancer (ERSPC) database and sta-
tistical methods are described. In Section ‘Results’, the
constructed multiple imputation model and the 20 mul-
tiply imputed datasets created are presented as well as
cause-specific and net survival. Sensitivity analyses results
devoted to testing the robustness of our model are also
exposed. A discussion concludes the paper.
Methods
ERSPC database
This study included 2844 men, aged between 56 and
78 years old, presenting with a prostate cancer and
included in the ERSPC [19–21] from 2003 to 2011, in
the Hérault department, France. The clinical variables
were completed from the Hérault cancer register, and the
causes of death from the ERSPC.
The following clinical variables were recorded: PSA level
at diagnosis (ng/ml), clinical staging (cT,cN,cM) based on
tumour size, regional lymph nodes and metastasis, type of
first treatment, Gleason score, PSA level post treatment
(ng/ml) and pathological staging (pT,pN,pM). Comorbidi-
ties and residual tumour after surgery were not taken into
account as these data had not been collected for the whole
study.
Clinical tumour stages (cTstage) were categorized as
1a,1b,1c for a tumour present but not detectable clini-
cally or with imaging, 2a,2b,2c for a circumscribed tumour
in the prostate tissue and stages 3a, 3b and 4 when
the tumour had invaded the capsule or other nearby
structures. Clinical N and M stages were coded 0/1
for absence/presence, respectively. Since the pathological
stagings pT and pN are available only when a surgical pro-
cedure is performed, we included 2 new variables labelled
Tnew and Nnew that are equal to pT, pN, respectively
provided that the first treatment is surgery (we did not
consider other surgical treatment), and these were equal
to cT, cN, otherwise. Note that we always have cM=pM
because there are very few biopsies.
The Gleason score was used to evaluate the prognosis of
prostate cancer. This score is based on the degree of differ-
entiation of the tumour. The score was taken from Glea-
son biopsy, not collected from Gleason prostatectomy.
This score is the sum of the two grades (ranging from 1
to 5) most often represented in the analysed tumour. It
ranges from 2 to 10. Gleason scores of 2 to 6 were cate-
gorized as “low risk”, Gleason 7 as “intermediate risk” and
Gleason 8 to 10 as “high risk”.
The first treatment was coded as surgery, hormone ther-
apy, chemotherapy, radiotherapy, high intensity focused
ultrasound (HIFU) or surveillance. In order to form large
enough groups of patients with the same level of risk,
we grouped together those who were undergoing hor-
mone therapy and chemotherapy and also those under
surveillance and HIFU. Note that surveillance includes
both watchful waiting and active surveillance.
We also used the d’Amico [22] generalized score built on
the PSA level at the onset of diagnosis, the clinical stage
T,N,M and the Gleason score. Four groups were formed as
described in the Additional file 1.
To analyse the effect of age at diagnosis, PSA level at
diagnosis and PSA level after treatment of prostate can-
cer, we considered these variables in a continuous form.
Note that the expected PSA level after treatment varies
according to the treatment.
All variables were categorized according to urologists
opinion.
For the patients who died, information on their dates
of death was obtained from the National Directory for
the Identification of Natural Persons (RNIPP). The RNIPP
identifies the vital status in France.
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Causes of death were obtained from the CépiDc (French
epidemiology centre of the medical causes of death) for
the patients who had died before December 31st, 2010.
The causes of death for all patients who died after Decem-
ber 31st, 2010 were missing because the request had not
yet been made to CépiDC. Among the patients who died
(322), patients with prostate cancer as cause of death (53
patients) and prostate cancer mentioned in part 1 of death
certificate (2 patients) were considered died of prostate
cancer. Other patients with observed cause of death (106
patients) were considered dying of other causes. Conse-
quently there are 161 patients (50%) with cause of death
missing.
Follow-up was performed up to June 30, 2013 (end point
date). The duration of follow-up was defined as the time
elapsed between diagnosis and death if the patient had
died, and the date of last news if the patient was lost
from follow-up, and the censoring date otherwise. Forty-
six patients were excluded because their dates of last news
was the same as the date of diagnosis.
The shortest follow-up time was 1 day, and the longest
almost 10 years (3624 days). The mean follow-up time
was 1822 days (almost 5 years) and the median 1853 days
(slightly more than 5 years).
Data used in this study are publicly available and
approved by two ethical committees for studies using
human subjects (National Data Processing Consultative
Committee for Medical Research-CCTIRS- and by the
Commission Nationale Informatique et Libertés-CNIL)
which provided approval to access at population-based
cancer, ERSPC and RNIPP data in Hérault and advo-
cates that all medical information are confidential and
anonymous (declaration n° 900075).
MAR hypothesis
Missing data mechanism, which is the process that gov-
erns the probability of being missing, can be classified into
three categories [23]:
• Missing Completely At Random (MCAR): the
probability of missingness depends neither on the
observed data nor on missing data.
• Missing At Random (MAR): the probability of
missingness may depends on the observed data but
not on missing data values.
• Missing Not At Random (MNAR): the probability of
missingness depends on the observed data and on
missing data values.
From these, the MAR assumption is a starting point in
multiple imputation since MICE performs well when it
holds. We examined all the variables to be imputed and
explained the reason of missingness. As MAR hypothe-
sis is essential, it is important to assess it, especially for
the cause of death variable that has 50% of missing values.
Even if they are not widely used and their practical value
is unclear, Enders [24] proposed 2 tests to assess MCAR
versus MAR. Note that it is impossible to test MNAR ver-
sus MAR because one would need missing information.
The first method, proposed by Dixon [25], uses a series of
independent t-tests to compare missing data subgroups,
and the second one, by Little [26], uses a multivariate
extension of the t-test approach.
Dixon’s test was performed on all the variables and, in
particular, for the cause of death. This approach sepa-
rates the missing and the complete cases on a particular
variable and uses a t-test to examine group mean dif-
ferences on other variables in the data set. The MCAR
mechanism implies that the cases with observed data
should be the same as the cases with missing val-
ues, on average. Therefore, if all the tests were non-
significant, data were considered as MCAR; otherwise,
a significant test suggested that the data were MAR or
MNAR [24].
For quantitative variables (age at diagnosis, PSA level
at diagnosis and PSA level after treatment) a Mann-
Whitney-Wilcoxon test was used to explore whether the
means were equal between the subgroups of observed
versus non-observed variables tested. For qualitative vari-
ables (First treatment, cTstage, cNstage, cMstage, Glea-
son, pTstage, pNstage) the Fisher’s exact test was per-
formed.
Moreover, distributions of patient’s characteristics were
compared between completed causes of death andmissing
causes of death.
Multiple imputation method andmodel
We used multiple imputation by chained equation [27, 28]
to create 20 multiply imputed datasets. Incomplete vari-
ables were imputed under fully conditional specification
[29] because of its flexibility to specify the method and the
set of predictors to be used for each incomplete variable.
Calculations were made in R 3.0.2 [30] using the mice
package [31].
The main variable of interest to impute was the vari-
able cause of death, with 50% missing data. All variables
available and the related number of missing values are dis-
played in Table 1. They were all imputed; 4,961 out of
23,272 records (21.3%) were incomplete.
PSA at diagnosis, cTstage, cNstage, cMstage, Gleason,
first treatment, and PSA after treatment were imputed
with the default method in mice. Consequently, PSA at
diagnosis and PSA after treatment that are continuous
variables were imputed with a predictive mean matching
method [26]. cNstage and cMstage were imputed with a
logistic regression method since it is a binary variable.
cTstage, Gleason and first treatment are categorical vari-
ables with more than 2 unordered categories, so they were
imputed under a multinomial logit model.
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Table 1 Number of missing values for the variables of interest
Variable Size Missing data Perc.




cT stage 589 20.7%
cN stage 1815 63.8%
cM stage 386 13.6%
First treat. 292 10.3%
Gleason 78 14.6%
PSA after treat. 770 27.1%
pT stage
Those who had surgery: 1521
92 6%
pN stage 601 39.5%
Perc. percentage, treat. treatment, diag. diagnosis
Cause of death was imputed with a logistic regression
method only if the patient was dead. Variables pNstage
and pTstage were imputed with a logistic regression
method and multinomial logit method, respectively, only
if there had been a surgical procedure. For cause of death,
pNstage and pTstage, special imputation functions were
created.
As derived variables, we had Tnew and Nnew (=cTstage
and cNstage, respectively, if no surgery procedure had
been performed and pTstage and pNstage, respectively,
if a surgical procedure had occurred) and d’Amico score
calculated from Gleason, PSA at diagnosis and cTstage.
To preserve the relationships in the data and the uncer-
tainty about these relationships we used a predictor
matrix created by quickpred [32]. The quickpred
function calculates correlations between variables and the
proportion of usable cases and combines them automati-
cally in amatrix [31]. Moreover, it is possible to specify the
minimum correlation and the proportion of usable cases.
As a starting predictor matrix, we defined the minimum
proportion of usable cases is at least 0.4 and the minimum
correlation is at least 0.1. Then, the clinicians specified the
set of predictors to be used for each variable to impute and
validated the predictor matrix.
Otherwise, since the complete-data model is a survival
model, we explored the interest of adding the event indi-
cator and the Nelson-Aalen estimator of the cumulative
hazard to the survival time, H(T), in the imputationmodel
as recommended by White and Royston [33]. The corre-
lation between H(T) and T was calculated and was equal
to 0.998. So, for these data, it matters little whether we
took H(T) or T as predictor [32]. Then, the correlations
between the variables to impute and H(T), T and event
indicator were calculated. As correlations don’t exceed 0.2,
two multiple imputation with and without time and event
indicator as predictors were performed, and we compared
the survival analysis. There were no differences between
the curves, so we decided not to take into account time
and event indicator in the imputation model. The predic-
tion matrix used in this imputation model is presented in
Table 2.
A visiting scheme was specified to choose an imputa-
tion order. Theoretically, the visiting scheme is irrelevant
as long as each column is visited often enough [31], but to
be more efficient, a clinical chronological order was cho-
sen: PSA at diagnosis, cTstage, cNstage, cMstage, Gleason,
first treatment, pTstage, pNstage, PSA after treatment and
cause of death.
Finally, Brand and Van Buuren [32, 34] have shown
that MICE algorithm can converge with just 5 itera-
tions. However, as some applications can require more
iterations and as computations are not tedious, we set
the number of iterations for this imputation model at
20.
Multiple imputation with m = 10, 20 and 30 multiply
imputed datasets were performed. Mean relative efficien-
cies for Kaplan-Meier estimator were calculated on each
m and were equal to 0.97, 0.99 and 0.99, respectively. Sur-
vival analysis were compared on multiple imputation with
10, 20 and with 30 multiply datasets, there were no dif-
ferences between the curves and between the confidence
intervals. Since it is recommended to set the number of
multiple imputations to the average of missing data [35]
and there were 21% of missing values, m = 20 datasets
were kept.
Survival analysis
Three survival estimators were compared: Pohar Perme’s
estimator, Kaplan-Meier estimator and cause-specific
cumulative incidence estimator.
Pohar-Perme’s net survival was estimated on the origi-
nal data base without imputation. This method does not
require the causes of death: it uses the mortality rates of
the general population to estimate the survival. Pohar-
Perme’s net survival was calculated with the function
rs.surv of relsurv package [36].
The next step was to analyse the 20 multiply imputed
datasets with a cause-specific survival approach. Cause-
specific survival was firstly estimated using Kaplan-
Meier estimator when censoring other-cause deaths on
each dataset separately, with the survfit function of
survival package [37]. However, the cause-specific
estimates that are based on the imputation model can be
interpretable as estimates of net survival only if it is rea-
sonable to assume independence between prostate cancer
death and death from other causes than prostate cancer.
This assumption could hold if the causes of death are
correctly assigned.
Therefore, competing risks survival analysis was esti-












Table 2 Predictor matrix
Cause of death Age PSA diag. cT cN cM First treat. Gleason pT pN PSA after treat. Tnew Nnew d’Amico
Cause of death 0 1 1 0 0 1 1 1 0 0 1 1 1 1
Age 0 0 0 0 0 0 0 0 0 0 0 0 0 0
PSA diag. 0 1 0 1 1 1 0 1 0 0 0 0 0 0
cT 0 1 1 0 0 0 0 1 0 0 0 0 0 0
cN 0 1 1 1 0 1 0 1 0 0 1 1 0 1
cM 0 1 1 1 0 0 0 1 0 0 0 0 0 0
First treat. 0 1 1 1 1 1 0 1 0 0 0 0 0 1
Gleason 0 1 1 0 1 1 1 0 0 0 0 1 0 0
pT 0 1 0 1 0 1 1 0 0 0 0 0 0 0
pN 0 1 0 1 0 1 1 0 0 0 0 0 0 0
PSA after treat. 0 1 1 0 0 1 1 0 0 0 0 1 0 0
Tnew 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Nnew 0 0 0 0 0 0 0 0 0 0 0 0 0 0
d’Amico 0 0 0 0 0 0 0 0 0 0 0 0 0 0
The rows correspond to variables to impute and the columns to the predictor. A 1 indicates that the column variable is used as a predictor to impute the row variable
Diag. diagnosis, treat. treatment
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Table 3 Distribution of baseline covariates for completed and missing causes of death and for all the patients
Observed Missing
χ2 Total (N=2844)cause of death cause of death
(n=161) (n=161)
No. of No. of No. of
patientsa % patientsa % P-value patients %
Age, years 0.82
≤ 70 102 63 99 61 1931 68
> 70 59 37 62 39 913 32
PSA at diagnosis, ng/ml 0.62
Missing 28 17 14 9 177 6
≤ 10 70 44 72 45 1952 69
> 10 63 39 75 46 715 25
cT stage 0.37
Missing 38 24 21 13 589 21
cT1 58 36 52 32 1430 50
cT2a 15 9 17 11 243 9
cT2b 8 5 13 8 147 5
cT2c 19 12 20 12 212 7
cT3/cT4 23 14 38 24 223 8
cN stage 0.95
Missing 138 86 112 70 1815 64
0 16 10 36 22 978 34
1 7 4 13 8 51 2
cM stage 0.13
Missing 35 22 28 17 386 14
0 87 54 104 65 2355 2355
1 39 24 29 18 103 4
First treatment 0.92
Missing 28 17 20 12 292 10
Surg. 51 32 51 32 1521 53
Radio. 23 14 28 17 467 16
Surv.+HIFU 5 3 4 2 111 5
Horm.+chemo. 54 34 58 36 453 16
Gleason 0.02
Missing 14 9 8 5 78 3
2-6 68 42 50 31 1393 49
7 42 26 66 41 1150 40
8-10 37 23 37 23 223 8
d’Amico generalized 0.26
Missing 27 17 7 4 291 10
Low 27 17 23 14 800 28
Intermediate 35 21 49 30 1136 40
High+Locally adv. 32 20 46 29 483 17
N++M+ 40 25 36 22 134 5
pT stage 0.80
Missing 116 72 117 73 1402 49
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Table 3 Distribution of baseline covariates for completed and missing causes of death and for all the patients (Continued)
pT2a 10 6 11 7 280 10
pT2b 13 8 9 5 314 11
pT2c 14 9 14 9 619 22
pT3/pT4 8 5 10 6 229 8
pN stage 0.69
Missing 130 81 123 77 1911 67
0 25 15 28 17 891 31
1 6 4 10 6 42 2
PSA after treat., ng/ml 0.68
Missing 72 45 55 34 770 27
≤ 0.07 26 16 35 22 1145 40
> 0.07 63 39 71 44 929 33
Surg. surgery, radio. radiotherapy, surv, surveillance, Horm, Hormone therapy, chemo. chemotherapy, inter, intermediate, treat, treatment
aNumber of deceased patients
competing risks, with the cuminc function of cmprsk
package [38].
Rubin’s rules after complementary log-log transformation
The 20 Kaplan-Meier survivals and the 20th compet-
ing risks survivals were pooled using Rubin’s rules after
complementary log-log transformation [39] to obtain the
two pooled cause-specific survival and their confidence
interval. As far as we know, Rubin’s rules after comple-
mentary log-log transformation were never presented in
the literature.
In the first paragraph, Rubin’s rules [40] are remem-
bered and then Rubin’s rules after complementary log-log
transformation are presented.
Rubin’s rules [40]:
Let Q be the parameter of interest. After the multiple
imputation, we had Qˆi, i = 1, ...,m wherein m was the
number of multiple imputations, and Ui, i = 1, ...,m the
estimated variance for each imputed data set.





And the total variance for this estimate was










was the pooled variance and







was the between-imputation variance.
Rubin’s rules after complementary log-log transformation:
In our study, the parameters of interest are the survival
probabilities and their confidence intervals.
For each imputed data set, at each time tj, j = 1, ..., J ,
we obtain the survival probabilities Sˆi(tj), i = 1, ...,m and
their variance V [Sˆi(tj)], i = 1, ...,m.
According to Marshall et al. [39], the correct way of
combining survival probabilities is to use Rubin’s rules
after complementary log-log transformation.







So by applying the equation (1) of Rubin’s rules we













We also define, for i = 1, ...,m and j = 1, ..., J








In order to obtain Ui(tj) depending on V [Sˆi(tj)], we use
the δ-method [41]:
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Table 4 Rˆ statistics of imputed variables
Var. Cause of PSA at cT cN cM First Gleason pT pN PSA after treat.
death diag. treat
Rˆ 1.04 0.99 1.01 1.07 1 0.99 1.02 0.99 1 0.99








log(1 − Sˆi(tj)) × (1 − Sˆi(tj))
]2




















And using equation (2) the total variance for Q¯ is:





By definition, the 95% confidence interval is:[
Q¯(tj) − 1.96
√




The pooled survival probabilities and the pooled confi-
dence interval at each time tj, j = 1, ..., J must then be back
transformed by 1 − exp(− exp()), and we obtain:
S¯(tj) = 1 − exp(− exp(Q¯(tj))) (5)
CI95(tj) =
[







We tested our multiple imputation model on a complete
dataset, from which we randomly removed different per-
centages of causes of death. For this, we created a sub
database with all the 161 dead patients with a known cause
of death (on the 322 initially deceased patients) and with
half of patients still alive randomly selected, in order to
have a proportion of dead/alive patients similar to the one
for the whole database.
Thereby, the created sub-database was composed of
1422 patients, 161 of whom had died and a cause of death
was identifiable. We could thus calculate the true cause-
specific survival. Of these 161 patients, 10%, 30%, 50%,
70% and 90% of causes of death were randomly removed
and the variables were imputed with the same imputation
model as before. As the variables were randomly removed,
MCAR hypothesis holds. For each case, we compared the
true cause-specific survival with the pooled cause-specific
survival after the imputations of causes of death had been
performed.
Secondmethod
In order to test our imputation model, we also con-
sidered the 20 first multiply imputed datasets from the
original data (2844 patients). For each imputed dataset,
the 161 original causes of death present in the origi-
nal data (106 deaths from other causes and 55 cancer
deaths) were deleted, and the 161 imputed causes of death
were retained. Thus, the MAR assumption still holds
if the original missingness mechanism is MAR. Then,
the 161 deleted causes of death were imputed using the
same imputation model as before. Twenty new multi-
ply imputed datasets were created, for each first multiply
imputed dataset.
Thirdmethod
The last sensitivity analysis was conducted by cross-
validation according to Gelman et al. [42]. The first 20
multiply imputed datasets were considered, as used above
in the second method. However, instead of removing all
the 161 original causes of death present in the original
data set, 161 causes of death were randomly removed
from these imputed datasets and the missing data were
re-imputed using the same imputation model. For each of
Table 5 Overall survival, net survival and cause-specific survivals of Kaplan-Meier and competing risks after multiple imputation with
their confidence intervals
Overall Net Pooled Kaplan-Meier Pooled competing risks
1 year 0.98 [0.98-0.99] 1.01 [1-1.01] 0.995 [0.992-0.997] 0.995 [0.991-0.997]
3 years 0.94 [0.93-0.95] 0.99 [0.99-1] 0.975 [0.968-0.981] 0.976 [0.969-0.981]
5 years 0.89 [0.88-0.91] 0.99 [0.98-1] 0.962 [0.952-0.970] 0.963 [0.954-0.971]
10 years 0.81 [0.78-0.83] 1.01 [0.98-1] 0.937 [0.915-0.955] 0.941 [0.921-0.957]
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Fig. 1 Overall, net, and pooled cause-specific survival curves and their confidence intervals
the first 20 multiply datasets the true and pooled cause-
specific survival were compared.
Results
MAR hypothesis
For themain variable of interest, i.e. cause of death, among
the 322 patients who died, 170 had died before December
31st, 2010 and 152 had died after December 31st, 2010.
Among the 170 patients who had died before Decem-
ber 31st, 2010, there were 9 missing causes of death.
The causes were missing because the CépiDC did not
find these patients (e.g. moving abroad). Among the 152
patients who had died after December 31st, 2010, there
were 152 missing causes of death, because the request had
not been made to the CépiDC. So, the causes of death
seemed to be MAR.
Table 6 Overall survival, net survival and cause-specific survivals of Kaplan-Meier and competing risks after multiple imputation with
their confidence intervals according to age
Overall Net Pooled Kaplan-Meier Pooled competing risks
[56;65]
1 year 0.99 [0.99-1] 1 [0.99-1.01] 0.996 [0.989-0.999] 0.996 [0.989-0.999]
3 years 0.96 [0.95-0.97] 0.99 [0.98-1.01] 0.983 [0.972-0.991] 0.983 [0.972-0.991]
N=867
5 years 0.93 [0.91-0.95] 0.99 [0.98-1.02] 0.977 [0.963-0.987] 0.977 [0.964-0.987]
10 years 0.86 [0.82-0.9] 0.99 [0.94-1.04] 0.951 [0.917-0.974] 0.953 [0.922-0.974]
[65;70]
1 year 0.99 [0.99-1] 1.01 [1.01-1.02] 0.997 [0.991-0.999] 0.997 [0.991-0.999]
3 years 0.93 [0.92-0.95] 0.99 [0.98-1.01] 0.976 [0.964-0.985] 0.976 [0.964-0.985]
N=1064
5 years 0.89 [0.87-0.91] 0.98 [0.96-1] 0.955 [0.938-0.969] 0.957 [0.940-0.970]
10 years 0.79 [0.75-0.84] 0.99 [0.95-1.05] 0.933 [0.897-0.960] 0.937 [0.905-0.962]
[70;++]
1 year 0.97 [0.96-0.98] 1 [0.99-1.01] 0.992 [0.983-0.996] 0.992 [0.984-0.996]
3 years 0.91 [0.90-0.94] 0.99 [0.98-1.01] 0.966 [0.951-0.977] 0.967 [0.953-0.978]
N=913
5 years 0.85 [0.82-0.88] 0.99 [0.96-1.02] 0.952 [0.931-0.969] 0.954 [0.934-0.970]
10 years 0.76 [0.70-0.83] 1.05 [0.97-1.14] 0.926 [0.871-0.963] 0.931 [0.884-0.964]
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For the other variables, the reasons for missingness were
due to incomplete medical files, or errors of data entry, so
they seemed to be MAR.
The Dixon’s tests [25] were performed for all the vari-
ables to imputed. For each variable, a binary missing
data indicator was created. Independent Mann-Whitney-
Wilcoxon tests and Fisher’s exact tests were used to assess
difference between the two groups created by the indica-
tor on quantitative and qualitative variables, respectively.
For the variable cause of death, the Mann-Whitney-
Wilcoxon tests for age at diagnosis, PSA level at diag-
nosis and PSA level after treatment were not statistically
significant, p-values were equal to 0.98, 0.61 and 0.14,
respectively. The Fisher’s exact tests for cTstage, cNstage,
cMstage, first treatment, Gleason, pTstage and pNstage
were also not statistically significant (taking into account
repeat testing) with p-values equal to 0.37, 0.78, 0.13, 0.60,
0.04, 0.81 and 0.57, respectively. It thus indicated that the
causes of death were MCAR.
On other variables to impute, Dixon’s tests were sta-
tistically significant for at least one variable. This means
that other variables to imputed were not MCAR, but were
MAR (as suspected above) or MNAR.
Moreover, distribution of patient’s characteristics was
compared for completed and missing causes of death. The
distribution was similar for completed and missing causes
of death, see Table 3. So for all variables to impute, we
assumed that the data were MAR.
Imputation model convergence and diagnostics.
Multiple imputation convergence per variable is shown in
the Additional file 2. The streams are freely intermingled
Fig. 2 True cause-specific, pooled cause specific survival rates and their confidence intervals using the first sensibility method
Morisot et al. BMCMedical ResearchMethodology  (2015) 15:54 Page 11 of 14
with each other, without showing any definite trends [32],
so the convergence is diagnosed. Moreover, we calculated
the Rˆ statistic [43]. If it is smaller than 1.1 (i.e. the dif-
ference of the within and between-variance is trivial), the
imputation is considered as convergent [44]. As we can
see on Table 4, all the Rˆ statistics are smaller than 1.1,
indicating the imputation convergence.
Diagnostics for multiple imputation models consist in
evaluating the difference between observed and imputed
data. For the two quantitative variables, PSA at diagno-
sis and PSA after treatment, distributions of observed and
imputed data were similar. Qualitative variables were also
compared for observed and imputed values.
For the main variable of interest, cause of death, 161 val-
ues were observed and 161 were imputed. Out of the 161
values observed, 106 (65.8%) of them were “other causes”
and 55 (34.2%) were “prostate cancer”. Considering the
20 imputed values of “other causes” and “prostate cancer”,
minimum values were equal to 43 and 96, respectively,
maximum values were equal to 65 and 118, means were
equal to 52.90 (32.9%) and 108.1 (67.1%) and medians
were equal to 53 and 108, respectively. χ2 tests were per-
formed to test the differences between imputed values and
observed values for the means, minimum and maximum
values. The p-values were equal to 0.89, 0.63 and 0.88,
respectively. Percentages of observed and imputed values
were also similar for the other qualitative variables. We
therefore concluded that the imputations could be used to
complete the missing data for the variables involved.
Survival analysis
Table 5 displays the overall, net and pooled cause-specific
survivals of Kaplan-Meier and competing risks rates (%)
at 1, 3, 5 and 10 years, together with their confidence
intervals. The results were satisfactory for the two pooled
cause-specific survival rates after MI, but not for net
survival (1.01% at 1 year and 10 years).
Figure 1 shows the overall, net, and the two pooled
cause-specific survival curves. The net survival exceeded
100% for almost the first 2 years of follow-up, then it
Fig. 3 True cause-specific, pooled cause-specific survival rates and their confidence intervals using the second sensibility method
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decreased and was finally still greater than 100% after
9 years. The pooled cause-specific survival using the
Kaplan-Meier estimator decreased slowly and then stabi-
lized at around 94% at 9 years of follow-up. This is proba-
bly because the likelihood of death from other causes was
higher than the likelihood of death from cancer, particu-
larly for aged patients, and because the mortality rates for
men in the general population are not representative of
men with prostate cancer. The pooled cause-specific sur-
vival using competing risks method was almost equal to
that of Kaplan-Meier estimator.
Table 6 displays overall, net and pooled cause-specific
survivals of Kaplan-Meier and competing risks (%) at 1, 3,
5 and 10 years and their confidence intervals according to
age. The results were similar to Table 5, the two pooled
cause-specific survivals after multiple imputation were
satisfactory, the older the patients, the worse the survival.
In contrast, net survival results were questionable, with
a net survival of 105% at 10 years for older patients.
Again, the pooled cause-specific survival using competing
risks method was almost equal to that of Kaplan-Meier
estimator.
Sensitivity analysis for multiple imputation method
In the previous paragraph, we have seen that the pooled
cause-specific survivals of Kaplan-Meier and competing
risks were nearly equal. In this section, only Kaplan-
Meier cause-specific survival was performed to test the
sensibility of our multiple imputation model.
First method
As can be seen in Fig. 2, the true cause-specific survival
curve and the pooled cause-specific survival curve were
confounded for up to 70% of removed causes of death. For
90% removed causes of death, the pooled cause-specific
survival underestimated the true cause-specific survival,
but this remained in the confidence interval of the latter.
Thus, with our 50% of missing causes of death, and
our imputation model, it appears that we obtained a good
estimation of the cause-specific survival.
Fig. 4 True cause-specific and pooled cause-specific survival rates and their confidence intervals using the third sensibility method
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Secondmethod
Figure 3 shows the true and the pooled cause-specific
survival rates estimated for each of the 20 first multi-
ply imputed datasets. The survival estimates provided by
our imputation model were in agreement with the true
cause-specific survival.
Thirdmethod
The results are displayed in Fig. 4. The results were sat-
isfactory. Indeed, the true cause-specific survival always
remained in the confidence interval of the pooled cause-
specific survival.
Discussion
On the basis of prostate cancer data, we estimated the two
pooled cause-specific survival rate using Kaplan-Meier’s
[18] estimator and competing risks after multiple imputa-
tion, as well as the net survival rate using Pohar-Perme’s
estimator [5].
By definition, net survival presupposes that prostate
cancer was the only cause of death. When considering
cause-specific survival of Kaplan-Meier, the event is death
by prostate cancer, and death by other causes is cen-
sored. Causes of death are not required when estimating
net survival, which is a very useful method, but, con-
versely, based on the general population mortality rate.
Since Kaplan-Meier estimates can only be interpreted as
estimates of net survival if it is reasonable to assume inde-
pendence between prostate cancer death and death from
other causes, we also estimated cause-specific cumulative
incidence estimator, accounting for deaths due to other
causes as competing risks. Survivals were almost equal,
so it was reasonable to assume independence between
prostate cancer death and death from other causes.
This work has some limitations. Assuming that the
assumptions of the models were verified, Pohar-Perme’s
and Kaplan-Meier’s estimators should theoretically esti-
mate the same quantity; however, we showed that this
was not the case, probably because men presenting with
prostate cancer are not representative of men presenting
with a cancer in the general population.
Cause-specific survival appeared as more precise, but
obtaining the causes of death is very difficult in practice;
it assumes that the causes of death are accurate whereas it
is very difficult to gather all the causes of death in a large
sample.
Therefore, we used the multiple imputation method to
overcome this difficulty and calculated the cause-specific
survival. Our results are satisfactory even when apply-
ing a 50% missing rate for causes of death, because the
MAR hypothesis holds for the variable causes of death.
Moreover, with the first method of sensitivity analysis, on
the sub database of 1422 patients, the multiple imputa-
tionmodel correctly estimated themissing causes of death
as up to 50% missing and the results of the Gelman’s
cross-validation [42] validated our imputation model.
However, depending on the objectives, this method may
not be applicable to very large databases for example, since
the multiple imputation method is demanding in terms
of time resources. Nevertheless, it is affordable when
databases are not too large.
Conclusion
In our data set, the results obtained by multiple imputa-
tion appeared to be better and more realistic than those
obtained using the net survival rate. Thus, we wonder
whether it would perhaps bemore efficient to usemultiple
imputation first, rather than net survival, when a repre-
sentative subsample of causes of death being completed is
validated by experts.
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(PDF 38 kb)
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